ICROM is an API CDMO specialized in development and GMP manufacturing of Active Ingredients; with over 50 years of experience, ICROM is the partner of choice for pharmaceutical outsourcing, able to provide a wide range of tailored services, custom development and custom manufacturing of NCEs, generic APIs, ‘high-tech’ and difficult to make molecules for complex formulations.
Leveraging sophisticated know-how, we build high-tech solutions to create complex molecules.
Everything we do for our Customers is driven by a deep passion and the firm belief that Public Health needs high expertise, high quality products, as well as tailor made, fast and reliable solutions.
ICROM was established by a French entrepreneur, Jean Epuran, as chemical industry for the manufacturing of Active Ingredients for Synthelabo (subsequently merged with Sanofi)
ICROM was acquired by Protex International, a private and family- owned multinational industrial group headquartered in Paris.
The Moor family founded Proxis Développement group as a spin-off of Protex International. ICROM became part of Proxis group, under the leadership of the third generation of the family (Arnaud Moor).
ICROM acquired 6,000 sqm of land adjacent to the existing facility, effectively doubling its surface.
From then, the Company started an important and fruitful period of investments which led to the construction of three new buildings, the revamping of production workshops, the acquisition, in 2018 of an additional piece of land of 3,500 sqm area and a number of additional expansion programs that are currently ongoing and some yet to come.
ICROM provides its services to the global pharmaceutical market, partnering with customers in more than 40 Countries across the Globe, from Europe to North America (USA), from Japan to China, from Middle East to India and Latin America.